New dopamine agonist enters Parkinson disease care - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

New dopamine agonist enters Parkinson disease care

The once-daily treatment selectively targets D1/D5 receptors and may be used with or without levodopa.

  • By

  • Kathryn Wighton

  • September 29, 2026

  • 2 min

Share

  • 1

    The FDA approved tavapadon (Juvmo) for treating adults with Parkinson disease, as announced by AbbVie.

  • 2

    The approval was based on the phase 3 TEMPO clinical trial program evaluating tavapadon in early Parkinson disease.

  • 3

    In TEMPO-1, tavapadon improved daily living activities at week 26 compared to placebo, with significant score reductions.

  • 4

    TEMPO-3 showed that tavapadon increased daily 'on' time without troublesome dyskinesia compared to placebo.

  • 5

    Common mild to moderate adverse events included nausea, dizziness, and headache, with specific events varying by treatment.

Original Source(s)

New dopamine agonist enters Parkinson disease care

  • by Kathryn Wighton

  • September 29, 2026

Related Content

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

Female patients less likely to receive invasive care

Review identifies recurring sex-based differences across specialties, including lower use of intensive and guideline-compliant treatment among female patients.